The inhibition of the degradation of DYRK2 by using vitamin K3 leads to increased apoptosis and reduced self-renewal of murine and human CML stem/progenitor cells. The gene discussed is DYRK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.